Enzyre
Private Company
Total funding raised: $3M
Overview
Enzyre is a private, pre-revenue diagnostics company developing a novel point-of-care platform for blood coagulation monitoring. Its ENZYSYSTEM integrates a proprietary chemiluminescent detection technology with a microfluidic cartridge and a handheld processor, aiming to deliver lab-quality multi-parameter coagulation tests outside the central lab. The company's initial focus is on improving the management of chronic bleeding disorders like hemophilia, with the goal of providing patients and physicians with immediate, actionable data to optimize therapy. Enzyre is supported by European grants and is positioning its platform for broader diagnostic applications through future collaborations.
Technology Platform
The ENZYSYSTEM is a portable, near-patient diagnostics platform for blood coagulation analysis. It integrates a proprietary chemiluminescent detection technology (using latent luciferin-protected peptide substrates) with a microfluidic cartridge (ENZYCARD), a handheld processor (ENZYPAD), and a mobile/cloud interface to deliver lab-quality, multi-parameter test results in real-time outside the central laboratory.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Enzyre competes in the point-of-care coagulation testing market against large, established players like Roche (CoaguChek), Abbott, and Siemens Healthineers, which offer simpler, often single-parameter devices. Its differentiation lies in offering multi-parameter, lab-comparable quality in a portable format with cloud connectivity. It also faces potential competition from other startups developing novel POC coagulation technologies.